Lopinavir

Generic Name: Lopinavir

Brand Names: Kaletra

Drug Type: Small Molecule

Chemical Formula: C_₃₇H_₄₈N_₄O_₅

CAS Number: 192725-17-0

Unique Ingredient Identifier: 2494G1JF75

Background: Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and ...

Indication: 用于高效抗逆转录病毒疗法（HAART）的组成药物。

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

A Study of Combination Therapies to Treat COVID-19 Infection

Phase 2

Withdrawn

Conditions: SARS Pneumonia
Corona Virus Infection
Coronavirus Infection
Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
Coronavirus-19
COVID
SARS-CoV 2
COVID-19

Interventions: Drug: hydroxychloroquine
Drug: Azithromycin
Drug: Ritonavir
Drug: Lopinavir

First Posted Date: 2020-07-07

Last Posted Date: 2021-04-08

Lead Sponsor: ProgenaBiome

Registration Number: NCT04459702

Locations: 🇺🇸
ProgenaBiome, Ventura, California, United States

Evaluation of Low-dose Darunavir in a Switch Study

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Darunavir
Drug: Lopinavir

First Posted Date: 2016-02-02

Last Posted Date: 2018-06-26

Lead Sponsor: Willem Daniel Francois Venter

Target Recruit Count: 300

Registration Number: NCT02671383

Locations: 🇿🇦
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Phase 2

Terminated

Conditions: HIV Infections

Interventions: Drug: Raltegravir (MK-0518)
Drug: Tenofovir
Drug: Nevirapine
Drug: Emtricitabine
Drug: Lamivudine
Drug: Lopinavir
Drug: Ritonavir
Drug: Atazanavir
Drug: Darunavir

First Posted Date: 2014-04-17

Last Posted Date: 2019-04-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 11

Registration Number: NCT02116660

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Phase 3

Withdrawn

Conditions: HIV

Interventions: Drug: Lopinavir
Drug: Atazanavir

First Posted Date: 2010-12-07

Last Posted Date: 2012-11-08

Lead Sponsor: ANRS, Emerging Infectious Diseases

Registration Number: NCT01255371

Locations: 🇹🇿
NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital, Mbeya, Tanzania
🇿🇦
Tshepang clinic, Limpopo University, Pretoria, South Africa

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: Hodgkin Lymphoma
Stage I Adult Hodgkin Lymphoma
Stage II Adult Hodgkin Lymphoma
Stage IV Adult Hodgkin Lymphoma
Stage III Adult Hodgkin Lymphoma

Interventions: Drug: lopinavir
Drug: ritonavir
Genetic: polymerase chain reaction
Other: flow cytometry
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis

First Posted Date: 2010-07-20

Last Posted Date: 2022-12-01

Lead Sponsor: Mayo Clinic

Registration Number: NCT01165645

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Phase 2

Terminated

Conditions: Brain Tumor
Anaplastic Astrocytoma
Anaplastic Ependymoma
Anaplastic Oligodendroglioma
Brain Stem Glioma
Giant Cell Glioblastoma
Glioblastoma
Gliosarcoma
Mixed Glioma

Interventions: Drug: ritonavir
Drug: lopinavir

First Posted Date: 2010-03-29

Last Posted Date: 2013-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT01095094

Locations: 🇺🇸
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin

Phase 4

Completed

Conditions: Tuberculosis
HIV Infection

Interventions: Drug: Lopinavir

First Posted Date: 2008-10-13

Last Posted Date: 2015-05-19

Lead Sponsor: Oswaldo Cruz Foundation

Target Recruit Count: 30

Registration Number: NCT00771498

Locations: 🇧🇷
University of Espirito Santo, Vitoria, ES, Brazil
🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (IPEC), Rio de Janeiro, RJ, Brazil
🇧🇷
Instituto Oswaldo Cruz (IOC), Rio de Janeiro, RJ, Brazil

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2003-03-21

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 328

Registration Number: NCT00056641

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪
Boehringer Ingelheim Investigational Site, Stuttgart, Germany

and more 78 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy